Back to discover
Drug

Vericiguat

Approved · EMA
Emerging researchLate-stage developmentRising momentum

Also known as Verquvo, Vericiguatum.

RxNorm2475830ChEMBLCHEMBL4066936UNIILV66ADM269
3
Research papers
15
Active clinical trials
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

CONVERGE-HF: COgnitioN With VERiciGuat Evaluation in Heart Failure

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

Randomised Controlled Trial of Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)

Clinical trial2026-06-29Results expected Q3 2027 · ClinicalTrials.gov

Efficacy of Vericiguat in HFrEF Patients With Coexisting Severe Tricuspid Regurgitation and Right Heart Failure; Multicenter Pragmatic Randomized Controlled Trial

Clinical trial2026-06-25Results expected Q2 2028 · ClinicalTrials.gov

A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction (VALOR)

Clinical trial2026-06-22Results expected Q2 2032 · ClinicalTrials.gov

A Prospective, Observational, Single-arm Study to Evaluate the Efficacy and Safety of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure.

Clinical trial2026-06-01Primary completion · ClinicalTrials.gov

Vericiguat in Vasospastic Angina

Clinical trial2026-06-01Primary completion · ClinicalTrials.gov

A Multicenter, Randomized, Controlled Trial to Evaluate the Efficacy and Safety of Perioperative Vericiguat in Patients Undergoing Cardiovascular Surgery

Clinical trial2026-05-18Results expected Q4 2028 · ClinicalTrials.gov

Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial.

Research2025-08-30Lancet (London, England)

Approval: Verquvo (EMA)

Regulatory2021-07-16EMA

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.

Research2020-03-28The New England journal of medicine

Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.

Research2019-12-09European journal of heart failure

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Vericiguat
Aliases & brands
VerquvoVericiguatum
RxNorm CUI
2475830
ChEMBL ID
CHEMBL4066936
UNII
LV66ADM269
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2021-07-16
Latest approval
2021-07-16
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2021-07-16Approval
Approval: Verquvo (EMA)

Indication: Treatment of symptomatic chronic heart failure

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

29 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
29
registered trials across all phases
LATEST COMPLETION 2025
15
Active studies
12
Recruiting
14
Late-stage (III+)
13
Completed
1
Discontinued
PHASE DISTRIBUTIONn = 29
Phase 16Phase 29Phase 2 / 31Phase 32Phase 48Phase N / A3

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Efficacy of Vericiguat in HFrEF Patients With Coexisting Severe Tricuspid Regurgitation and Right Heart Failure; Multicenter Pragmatic Randomized Controlled Trial

Not yet recruitingPH IVDaejeon St. Mary's hospitaln=1002028

Vericiguat's Effects on Reverse Remodeling Indices: Pathophysiologic Approach to Treatment of Heart Failure With Reduced Ejection Fraction

RecruitingPH IVUniversity Medical Centre Ljubljanan=602027

The Effects of Soluble Guanylyl Cyclase Stimulation on Perioperative Vascular Reactivity and Organ Injury in Cardiac Surgery

RecruitingPH IVVanderbilt University Medical Centern=1702027

Impact of Vericiguat on Vascular Biology, as Well as Resting and Exertional Cardiovascular Performance Among Patients With Heart Failure With Reduced Ejection Fraction

Active, not recruitingPH IVUniversity of Colorado, Denvern=302027

Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction

Not yet recruitingPH IVDongying Zhangn=2002026

Recent completions

Trials that read out recently, adding to the completed evidence base.

Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction

CompletedPH IIJohns Hopkins Universityn=452025

A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction

CompletedPH IIIKey trialMerck Sharp & Dohme LLCn=6,1062025

The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation in Patients With Heart Failure With Reduced Ejection Fraction

CompletedPH IVJosef Stehlikn=262024

A Phase IV Interventional Post Approval Trial to Investigate Effectiveness and Safety of Vericiguat Therapy in Indian Patients With Chronic Heart Failure With Reduced Ejection Fraction After a Worsening Heart Failure Event.

CompletedPH IVBayern=2052024

A Phase 2b Open-label Clinical Study to Evaluate the Tolerability and Safety of an Initiation Dose of 5 mg of Vericiguat in Participants With Chronic Heart Failure With Reduced Ejection Fraction

CompletedPH IIBayern=1062024

A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT GlObal Study in Subjects With Heart Failure With Reduced EjectIon FrAction (VICTORIA)

CompletedPH IIIKey trialMerck Sharp & Dohme LLCn=5,0502019

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20192025
Major research themes4
Heart Failure1Heterocyclic Compounds, 2-Ring1Pyrimidines1Stroke Volume1
Journals, researchers & institutions
Top journals
  • European journal of heart failure1
  • Lancet (London, England)1
  • The New England journal of medicine1
Leading researchers
  • Anstrom KJ3
  • Butler J3
  • Lam CSP3
  • O'Connor CM3
  • Patel MJ3
  • Ponikowski P3
  • Voors AA3
  • Armstrong PW2
Leading institutions
free-text, unnormalised
  • Canadian VIGOUR Centre2
  • Duke Clinical Research Institute2
  • Wroclaw Medical University2
  • Baylor Scott and White Research Institute1
  • CardioVID Clinic-University of Antioquia1
  • Charité University Medicine1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.